Showing results (161-170 of 181) with videos related to

Sort By:
Pageof 19
Blood|January 14, 2025
Salvage autologous transplant in relapsed multiple myeloma: long-term follow-up of the phase 3 GMMG ReLApsE trialMarc-Andrea Baertsch, Jana Schlenzka, Thomas Hielscher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 27, 2023
Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple MyelomaLisa B Leypoldt, Diana Tichy, Britta Besemer, et al.
Blood|December 14, 2011
Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17pKai Neben, Henk M Lokhorst, Anna Jauch, et al.
Nature Genetics|November 26, 2024
Single-cell multiomics analysis reveals dynamic clonal evolution and targetable phenotypes in acute myeloid leukemia with complex karyotypeAino-Maija Leppä, Karen Grimes, Hyobin Jeong, et al.
Nature Communications|November 23, 2024
Multi-omic and single-cell profiling of chromothriptic medulloblastoma reveals genomic and transcriptomic consequences of genome instabilityPetr Smirnov, Moritz J Przybilla, Milena Simovic-Lorenz, et al.
BMC Cancer|April 27, 2016
Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myelomaMarc-Andrea Baertsch, Jana Schlenzka, Elias K Mai, et al.
Leukemia|July 23, 2020
Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsEHartmut Goldschmidt, Marc-Andrea Baertsch, Jana Schlenzka, et al.
Blood|June 13, 2015
Recurrent CDKN1B (p27) mutations in hairy cell leukemiaSascha Dietrich, Jennifer Hüllein, Stanley Chun-Wei Lee, et al.
Nature Genetics|November 29, 2011
Common variation at 3p22.1 and 7p15.3 influences multiple myeloma riskPeter Broderick, Daniel Chubb, David C Johnson, et al.
Nature Communications|August 27, 2024
Developmental signals control chromosome segregation fidelity during pluripotency and neurogenesis by modulating replicative stressAnchel de Jaime-Soguero, Janina Hattemer, Anja Bufe, et al.
Pageof 19